Blood Plasma: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024

SKU ID : WGR- 12990257

Publishing Date : 05-Sep-2018

No. of pages : 338

PRICE
4300
8600


  • The 2018 study has 338 pages, 148 tables and figures. Worldwide markets are poised to achieve continuing growth as animal and human blood is further fractionated to address more disease treatments and becomes more effective in the research and development aspects of medical care delivery.

    Blood is for most species the essence of life. Blood plasma provides significant health benefits. The varieties of proteins and other components of blood are in demand worldwide. Blood proves its value by managing a variety of ways to treat disease.

    The plasma proteins or derivatives in blood are extracted via the fractionation process. A range of valuable products are manufactured from blood plasma through fractionation. Fractionation occurs in tanks at near freezing temperatures. Fractionation is used to maintain the integrity of the proteins in plasma. This process includes a phase of introducing various viral inactivation procedures.

    Blood plasma offers high value for its volume and weight. One refrigerated container might be worth more than an entire shipload of grain. Blood provides significant health benefits to people. Blood exports boost U.S. exports with minimal carbon emissions.

    Liver disease is a major cause of illness and death worldwide. In China, 400 million people have liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]). Nonalcoholic fatty liver disease and alcoholic liver diseases are also prevalent diagnoses.

    The blood plasma market is driven in part by China, and by demand from China for high quality blood from the US. Chinese patients consumed 400 metric tons of serum albumin in 2017, half of the global total of that blood protein. The necessary supply could be provided by the Chinese population, but, many of them are afraid to donate blood.

    The reason is a well-remembered 1990s health scare in which tens of thousands of farmers who had been paid to donate blood acquired HIV from unsanitary needles. The ensuing scandal was covered up by the government.

    As a result, China has to import about 60% of its serum albumin—and the ever-rising demand has driven up prices. American companies have an edge in the Chinese markets because of the quality of the blood collected. The edge is apparent in the fact that three foreign companies account for 88% of China’s serum albumin imports.

    The billion-dollar market for blood worldwide has a variety of participants. Thermo Fsher Scientific has the largest market participation. Sales of blood therapeutics were $30.9 billion in 2017. By 2024, these products reach $57.5 billion, reflecting a five-year CAGR of 8.2%.

    Companies Profiled

    Market Leaders

    Thermo Fisher Scientific
    Takeda / Shire / Baxalta
    Grifols S.A
    Avantor / VWR
    Corning
    GE Healthcare
    Octapharma
    China Biologic Products Holdings
    ANZCO Foods / Bovogen Biologicals
    Biotest
    Global Cord Blood
    Rocky Mountain Biologicals

    Key Topics

    Blood
    Plasma proteins
    Immunoglobulins
    Albumin
    Hemophilia factor proteins
    Fractionation
    Serum
    Blood Plasma
    Proteins Components of Blood
    Liver Disease
    Viral Hepatitis (Predominantly Hepatitis B
    Mandatory HCV Screening
    Blood Transfusion
    High Mortality From Liver Diseases
    Serum Albumin, A Substance Found In Human Blood Plasma
    Blood Acquired HIV from Unsanitary Needles